

# Isabelle Carole van Gelder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6022347/publications.pdf>

Version: 2024-02-01

168  
papers

18,752  
citations

36203

51  
h-index

13338

130  
g-index

169  
all docs

169  
docs citations

169  
times ranked

13717  
citing authors

#	ARTICLE	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
2	A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2002, 347, 1834-1840.	13.9	2,159
3	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020, 383, 1305-1316.	13.9	1,071
4	Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2010, 362, 1363-1373.	13.9	851
5	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
6	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	9.4	552
7	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
8	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2217-2228.	1.2	292
9	Verapamil Reduces Tachycardia-Induced Electrical Remodeling of the Atria. <i>Circulation</i> , 1997, 95, 1945-1953.	1.6	283
10	A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 313-321.	1.2	239
11	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 355-383.	0.5	233
12	Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1000-1007.	1.2	218
13	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Electrofisiología (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
14	Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. <i>European Heart Journal</i> , 2018, 39, 2987-2996.	1.0	203
15	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2018, 20, 1565-1565a0.	0.7	186
16	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16016.	18.1	185
17	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
18	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018, 39, 2942-2955.	1.0	181

#	ARTICLE	IF	CITATIONS
19	Lone Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1715-1723.	1.2	177
20	Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. <i>Cardiovascular Research</i> , 1999, 42, 443-454.	1.8	152
21	Antiarrhythmic drugs: clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732an.	0.7	144
22	Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. <i>Europace</i> , 2006, 8, 935-942.	0.7	141
23	Rate control in atrial fibrillation. <i>Lancet, The</i> , 2016, 388, 818-828.	6.3	140
24	Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 38-50.	1.0	131
25	Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. <i>Europace</i> , 2018, 20, e1-e10.	0.7	131
26	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	1.9	129
27	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
28	Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 21-28.	1.9	123
29	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
30	Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. <i>American Journal of Cardiology</i> , 1999, 84, 147-151.	0.7	120
31	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021, 121, 270-278.	1.8	118
32	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. <i>European Heart Journal</i> , 2021, 42, 4731-4739.	1.0	111
33	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021, 144, 845-858.	1.6	111
34	Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. <i>Heart Rhythm</i> , 2005, 2, 19-24.	0.3	104
35	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
36	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	1.2	91

#	ARTICLE	IF	CITATIONS
37	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2022, 43, 1219-1230.	1.0	84
38	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
39	RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. <i>American Heart Journal</i> , 2006, 152, 420-426.	1.2	76
40	The importance of whether atrial fibrillation or heart failure develops first. <i>European Journal of Heart Failure</i> , 2012, 14, 1030-1040.	2.9	70
41	QRS Area Is a Strong Determinant of Outcome in Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006497.	2.1	69
42	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	0.7	67
43	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018, 24, 177-185.	0.7	65
44	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409.	1.6	65
45	Nurse-led vs. usual-care for atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 634-641.	1.0	64
46	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	0.7	64
47	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. <i>Heart Rhythm</i> , 2014, 11, 1543-1550.	0.3	62
48	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 3793-3799c.	1.0	60
49	Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 393.	0.7	59
50	The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. <i>Europace</i> , 2006, 8, 943-949.	0.7	55
51	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. <i>Europace</i> , 2011, 13, 1517-1525.	0.7	55
52	Asymptomatic persistent atrial fibrillation and outcome: Results of the RACE study. <i>Heart Rhythm</i> , 2014, 11, 939-945.	0.3	51
53	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	1.0	50
54	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47

#	ARTICLE	IF	CITATIONS
55	Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. <i>European Heart Journal</i> , 2021, 42, 532-540.	1.0	46
56	Digoxin Delays Recovery From Tachycardia-Induced Electrical Remodeling of the Atria. <i>Circulation</i> , 1999, 100, 1836-1842.	1.6	45
57	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. <i>Cardiovascular Research</i> , 2022, 118, 2415-2427.	1.8	45
58	A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: Effects on clinical profile, neurohormones and survival. <i>International Journal of Cardiology</i> , 2006, 109, 95-100.	0.8	42
59	Research Priorities in Atrial Fibrillation Screening. <i>Circulation</i> , 2021, 143, 372-388.	1.6	42
60	EHRA White Paper: knowledge gaps in arrhythmia management—status 2019. <i>Europace</i> , 2019, 21, 993-994.	0.7	40
61	Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4563-4569.	1.8	39
62	Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. <i>Europace</i> , 2020, 22, 352-360.	0.7	39
63	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 348-357.	0.4	39
64	Comparison of strain imaging techniques in CRT candidates: CMR tagging, CMR feature tracking and speckle tracking echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 443-456.	0.7	38
65	Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. <i>Heart Rhythm</i> , 2020, 17, 1804-1832.	0.3	38
66	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
67	Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. <i>Europace</i> , 2020, 22, 1162-1172.	0.7	35
68	Cardiac resynchronization therapy in adults with congenital heart disease. <i>Europace</i> , 2018, 20, 315-322.	0.7	34
69	Atrial fibrillation progression and outcome in patients with young-onset atrial fibrillation. <i>Europace</i> , 2018, 20, 1750-1757.	0.7	34
70	The Role of Atrial Electrical Remodeling in the Progression of Focal Atrial Ectopy to Persistent Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 866-870.	0.8	33
71	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. <i>Europace</i> , 2020, 22, 66-73.	0.7	33
72	Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion for the Improvement of Rhythm Control for Persistent Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1001-1009.	1.2	32

#	ARTICLE	IF	CITATIONS
73	Effectiveness and safety of dabigatran versus acenocoumarol in "real-world" patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1319-1327.	0.7	32
74	Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007676.	2.1	30
75	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. <i>Europace</i> , 2014, 16, 1417-1425.	0.7	29
76	Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. <i>Heart Rhythm</i> , 2016, 13, 1777-1783.	0.3	27
77	Atrial reverse remodelling is associated with outcome of cardiac resynchronization therapy. <i>Europace</i> , 2016, 18, 1211-1219.	0.7	27
78	Relation of renal dysfunction with incident atrial fibrillation and cardiovascular morbidity and mortality: The PREVEND study. <i>Europace</i> , 2017, 19, 1930-1936.	0.7	26
79	The clinical value of regular thyroid function tests during amiodarone treatment. <i>European Journal of Endocrinology</i> , 2017, 177, 9-14.	1.9	26
80	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. <i>Europace</i> , 2020, 22, 1026-1035.	0.7	26
81	Does Myocardial Infarction Beget Atrial Fibrillation and Atrial Fibrillation Beget Myocardial Infarction?. <i>Circulation</i> , 2015, 131, 1824-1826.	1.6	25
82	Obesity is associated with impaired long-term success of pulmonary vein isolation: a plea for risk factor management before ablation. <i>Open Heart</i> , 2018, 5, e000771.	0.9	25
83	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <scp>VIP&HF</scp> study. <i>European Journal of Heart Failure</i> , 2020, 22, 1923-1929.	2.9	25
84	Strain imaging to predict response to cardiac resynchronization therapy: a systematic comparison of strain parameters using multiple imaging techniques. <i>ESC Heart Failure</i> , 2018, 5, 1130-1140.	1.4	24
85	Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implanTable cardIOverter defibrillator therapy and sudden cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). <i>Heart Rhythm</i> , 2021, 18, 785-792.	0.3	24
86	Long-term results of surgical minimally invasive pulmonary vein isolation for paroxysmal lone atrial fibrillation. <i>Europace</i> , 2015, 17, 747-752.	0.7	22
87	Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. <i>Europace</i> , 2020, 22, 1619-1627.	0.7	22
88	Update on management of atrial fibrillation in heart failure: a focus on ablation. <i>Heart</i> , 2022, 108, 422-428.	1.2	22
89	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. <i>Europace</i> , 2022, 24, 552-564.	0.7	22
90	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. <i>Europace</i> , 2020, 22, 1337-1344.	0.7	21
92	Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. <i>International Journal of Cardiology</i> , 2014, 171, 90-92.	0.8	20
93	Comparison of strain parameters in dyssynchronous heart failure between speckle tracking echocardiography vendor systems. <i>Cardiovascular Ultrasound</i> , 2017, 15, 25.	0.5	20
94	Atrial fibrillation: villain or bystander in vascular brain injury. <i>European Heart Journal Supplements</i> , 2020, 22, M51-M59.	0.0	20
95	Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. <i>Europace</i> , 2019, 21, 563-571.	0.7	19
96	Surgical Left Atrial Appendage Exclusion Does Not Impair Left Atrial Contraction Function: A Pilot Study. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	17
97	Prognostic Significance of Atrial Arrhythmias in a Primary Prevention ICD Population. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1070-1079.	0.5	16
98	Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm – A CIBIS II analysis. <i>Clinical Cardiology</i> , 2017, 40, 740-745.	0.7	16
99	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
100	Rate control drugs differ in the prevention of progression of atrial fibrillation. <i>Europace</i> , 2022, 24, 384-389.	0.7	14
101	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
102	Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study. <i>Europace</i> , 2016, 19, euw016.	0.7	13
103	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. <i>Europace</i> , 2016, 18, 191-200.	0.7	13
104	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2058.	0.5	13
105	Pulmonary vein anatomy addressed by computed tomography and relation to success of second-generation cryoballoon ablation in paroxysmal atrial fibrillation. <i>Clinical Cardiology</i> , 2019, 42, 438-443.	0.7	13
106	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	0.7	13
107	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, .	0.7	13
108	Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design. <i>Clinical Research in Cardiology</i> , 2018, 107, 539-547.	1.5	12

#	ARTICLE	IF	CITATIONS
109	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018, 122, 578-583.	0.7	12
110	Subclinical atherosclerosis is associated with incident atrial fibrillation: a systematic review and meta-analysis. <i>Europace</i> , 2020, 22, 991-1000.	0.7	12
111	ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project. <i>European Heart Journal</i> , 2022, 43, 1450-1452.	1.0	12
112	Clinical and electrophysiological predictors of device-detected new-onset atrial fibrillation during 3 years after cardiac surgery. <i>Europace</i> , 2021, 23, 1922-1930.	0.7	12
113	Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. <i>American Heart Journal</i> , 2017, 183, 49-53.	1.2	11
114	Risk Factors for Atrial Fibrillation Progression. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 201-209.	0.7	11
115	Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. <i>Europace</i> , 2021, 23, 1359-1368.	0.7	11
116	Telomere length and incident atrial fibrillation – data of the PREVEND cohort. <i>PLoS ONE</i> , 2017, 12, e0171545.	1.1	11
117	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
118	Association between heart failure aetiology and magnitude of echocardiographic remodelling and outcome of cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 645-653.	1.4	10
119	Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies. <i>Europace</i> , 2022, 24, 193-201.	0.7	10
120	Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation. <i>Heart Rhythm</i> , 2014, 11, 478-484.	0.3	9
121	STEEER-AF: a cluster-randomized education trial from the ESC. <i>European Heart Journal</i> , 2020, 41, 1952-1954.	1.0	9
122	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322.	0.7	9
123	Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the MARC study – authors reply. <i>Europace</i> , 2018, 20, 393-393.	0.7	8
124	Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study. <i>International Journal of Cardiology</i> , 2018, 272, 208-210.	0.8	8
125	Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation – Data from RACE 3. <i>American Heart Journal</i> , 2020, 226, 235-239.	1.2	8
126	Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010204.	2.1	8



#	ARTICLE	IF	CITATIONS
127	Rising prevalence of atrial fibrillation in the elderly population: new challenges of geriatric cardiology. <i>Europace</i> , 2019, 21, 1451-1453.	0.7	7
128	Spontaneous resolution of left bundle branch block and biventricular stimulation lead to reverse remodeling in dyssynchronopathy. <i>Journal of Electrocardiology</i> , 2016, 49, 696-698.	0.4	6
129	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020, 7, 1419-1429.	1.4	6
130	Incidence and outcome of atrial fibrillation: diversity throughout Europe. <i>European Heart Journal</i> , 2021, 42, 858-860.	1.0	6
131	Rate Control in Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 1597-1599.	1.6	5
132	Young-onset atrial fibrillation: Sex differences in clinical profile, progression rate and cardiovascular outcome. <i>IJC Heart and Vasculature</i> , 2019, 25, 100429.	0.6	5
133	Newly discovered atrial fibrillation: who(se) care(s)? <i>Europace</i> , 2020, 22, 677-678.	0.7	5
134	First-line treatment of persistent and long-standing persistent atrial fibrillation with single-stage hybrid ablation: a 2-year follow-up study. <i>Europace</i> , 2021, 23, 1568-1576.	0.7	5
135	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
136	Device-Detected Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2513-2515.	1.6	4
137	Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study. <i>IJC Heart and Vasculature</i> , 2020, 31, 100673.	0.6	4
138	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. <i>Europace</i> , 2022, 24, 910-920.	0.7	4
139	Cluster Individuals Based on Phenotype and Determine the Risk for Atrial Fibrillation in the PREVENT and Framingham Heart Study Populations. <i>PLoS ONE</i> , 2016, 11, e0165828.	1.1	3
140	Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation. <i>Evidence-Based Medicine</i> , 2017, 22, 107-108.	0.6	3
141	The left atrium: An overlooked prognostic tool. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 389-391.	0.8	3
142	Atrial Fibrillation During Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 179-192.	1.0	3
143	Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 787-789.	1.5	3
144	Segment length in cine (SLICE) strain analysis: a practical approach to estimate potential benefit from cardiac resynchronization therapy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 4.	1.6	3

#	ARTICLE	IF	CITATIONS
145	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillationâ€”a dedication to Harry Crijns. <i>Europace</i> , 2021, 23, ii34-ii39.	0.7	3
146	Aetiology of Heart Failure, Rather than Sex, Determines Reverse LV Remodelling Response to CRT. <i>Journal of Clinical Medicine</i> , 2021, 10, 5513.	1.0	3
147	Atrial Fibrillation During Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 735-748.	0.7	2
148	The link between atrial fibrillation and hereditary channelopathies: Authorsâ€™ reply. <i>Europace</i> , 2018, 20, 1872-1872.	0.7	2
149	Atrial fibrillation detected at screening is not a benign condition: outcomes in screen-detected versus clinically detected atrial fibrillation. Results from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. <i>Open Heart</i> , 2021, 8, e001786.	0.9	2
150	Case of the month by the EHRA Education committee: exercise-related arrhythmias. <i>Europace</i> , 2008, 10, 235-237.	0.7	1
151	Post-shock oversensing by a subcutaneous defibrillator resulting in inappropriate withholding of post-shock bradycardia pacing. <i>Europace</i> , 2014, 16, 1032-1032.	0.7	1
152	Atrial fibrillation: a mechanism or just a bystander?. <i>Europace</i> , 2017, 19, 1413-1415.	0.7	1
153	Lifestyle components: Self-reported physical activity, nutritional status, sleep quality and incident atrial fibrillation. <i>IJC Heart and Vasculature</i> , 2020, 27, 100492.	0.6	1
154	The road goes ever on: innovations and paradigm shifts in atrial fibrillation management. <i>Europace</i> , 2021, 23, ii1-ii3.	0.7	1
155	Identifying patients with atrial fibrillation recurrences after two pulmonary vein isolation procedures. <i>Open Heart</i> , 2021, 8, e001718.	0.9	1
156	Case of polymorphic ventricular tachycardia after stroke necessitating defibrillation. <i>Europace</i> , 2007, 10, 77-78.	0.7	0
157	Rate Control in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 419-427.	0.7	0
158	Response to Letter Regarding Article â€œTemporal Relationship Between Subclinical Atrial Fibrillation and Embolic Eventsâ€œ. <i>Circulation</i> , 2015, 131, e337-8.	1.6	0
159	Still many unanswered questions about rate control therapy in atrial fibrillation. <i>Evidence-Based Medicine</i> , 2016, 21, 180-180.	0.6	0
160	Impact of Thoracoscopic Pulmonary Vein Isolation on Right Ventricular Function: A Pilot Study. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	0
161	Integrated care to reduce atrial fibrillation burden: do not underrate the overweight!. <i>Europace</i> , 2018, 20, 1875-1876.	0.7	0
162	Response to Letter From Vereckei Regarding, â€œQRS Area Is a Strong Determinant of Outcome in Cardiac Resynchronization Therapyâ€œ. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007297.	2.1	0

#	ARTICLE	IF	CITATIONS
163	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectivenessâ€”Authorsâ€™ reply. <i>Europace</i> , 2020, 22, 1602-1602.	0.7	0
164	Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study. <i>American Heart Journal</i> , 2021, 244, 36-41.	1.2	0
165	Surgical Minimally Invasive Pulmonary Vein Isolation for Lone Atrial Fibrillation. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2013, 8, 410-415.	0.4	0
166	Hypercoagulability Promotes Atrial Fibrosis and Fibrillation. <i>Blood</i> , 2014, 124, 4246-4246.	0.6	0
167	New-onset perioperative atrial fibrillation in cardiac surgery patients: transient trouble or persistent problem?â€”Authorsâ€™ reply. <i>Europace</i> , 2021, , .	0.7	0
168	Early rhythm-control therapy efficacious in men and women with AF. , 0, , .		0